Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m |
||
Line 1: | Line 1: | ||
− | =Mechanism of action= | + | ==Mechanism of action== |
From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. | From the [http://www.cancer.gov/drugdictionary?CdrID=500479 NCI Drug Dictionary]: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons. | ||
− | = | + | ==Diseases for which it is used== |
+ | *[[Adult T-cell leukemia-lymphoma]] | ||
+ | *[[Cutaneous T-cell lymphoma]] | ||
+ | *[[Peripheral T-cell lymphoma]] | ||
− | == | + | ==History of changes in FDA indication== |
− | + | *8/8/2018: Initial FDA approval "for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy." | |
− | == | + | ==Also known as== |
− | + | *'''Code name:''' KW-0761 | |
− | + | *'''Generic name:''' mogamulizumab-kpkc | |
− | + | *'''Brand name:''' Poteligeo | |
− | |||
− | |||
[[Category:Drugs]] | [[Category:Drugs]] | ||
+ | [[Category:Intravenous medications]] | ||
− | |||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-CCR4 antibodies]] | [[Category:Anti-CCR4 antibodies]] | ||
[[Category:Anti-CD194 antibodies]] | [[Category:Anti-CD194 antibodies]] | ||
+ | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
[[Category:Cutaneous T-cell lymphoma medications]] | [[Category:Cutaneous T-cell lymphoma medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
− | [[Category: | + | [[Category:FDA approved in 2018]] |
Revision as of 17:54, 10 August 2018
Mechanism of action
From the NCI Drug Dictionary: A humanized monoclonal antibody directed against C-C chemokine receptor 4 (CCR4) with potential anti-inflammatory and antineoplastic activities. Mogamulizumab selectively binds to and blocks the activity of CCR4, which may inhibit CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, and chemokine-mediated angiogenesis. In addition, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and some types of neurons.
Diseases for which it is used
History of changes in FDA indication
- 8/8/2018: Initial FDA approval "for adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy."
Also known as
- Code name: KW-0761
- Generic name: mogamulizumab-kpkc
- Brand name: Poteligeo